Is it possible that advanced-stage gastric cancer patients can be cured by surgery alone?

Li, Yiu‐Tai; Chang, Wen-Hsun

doi:10.1097/jcma.0000000000000873

Cited by 6 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our limited knowledge, stage may be the most importantly independent prognostic factors for all solid tumors. 2–5 In fact, the authors have clearly demonstrated the strong correlation between the high NLRP12 expression and advanced stage of intracranial glioma, suggesting that the expression of NLRP12 may depend on the tumor stage or vice versa.…”

Section: Dear Editormentioning

confidence: 97%

The statistical significance may be mis-interpretated

Chang

2023

Journal of the Chinese Medical Association

Self Cite

View full text Add to dashboard Cite

Section: Dear Editormentioning

confidence: 97%

The statistical significance may be mis-interpretated

Chang

2023

Journal of the Chinese Medical Association

Self Cite

View full text Add to dashboard Cite

“…Thank you for your comments 1 for our article. 2 With regard to lymph node metastasis, gastric cancer with lymph node metastasis, which is limited to N1 or N2 (NCCN guideline), is classified as regional lymph node metastasis.…”

Section: Dear Editormentioning

confidence: 98%

Reply to “Is it possible that advanced-stage gastric cancer patients can be cured by surgery alone?”

Chen

et al. 2023

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

“…Dr Chen's study 12 showed 13.5% (n = 64) of GC patients have been treated with adjuvant chemotherapy; however, the current National Comprehensive Cancer Network© (NCCN) guidelines recommend adjuvant treatment rather than surgery alone in patients with pT3-4 and/or N+ GC. 9,18 Only 29% (n = 137) of GC patients did have negative lymph node metastases (N0); and additionally, 29% (n = 138) of GC patients were classified as pT1-2, suggesting the high possibility of risk of undertreatment in Dr Chen's group. 12 Multidisciplinary team or multimodality treatment is encouraged for advanced-stage cancer patients.…”

mentioning

confidence: 99%

“…The aforementioned argument has been raised by audience (Drs Li and Chang 18 ) who questioned whether surgery alone can be an adequate strategy in the management of advanced-stage GC patients. Dr Chen’s study 12 showed 13.5% (n = 64) of GC patients have been treated with adjuvant chemotherapy; however, the current National Comprehensive Cancer Network© (NCCN) guidelines recommend adjuvant treatment rather than surgery alone in patients with pT3-4 and/or N+ GC.…”

mentioning

confidence: 99%

Molecular pathology-integrated clinicopathological prognostic factors

Yang

Liu

Wang

2023

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Malignant diseases are the main and leading cause of death in Taiwan, contributing to an urgent need of active care for patients with malignant diseases, regardless whether the earlyor late-stage of diseases are defined. [1][2][3] Cancer treatment can be simply grouped into two distinguished therapeutic approaches; one is the highly curative therapy applied either by surgery alone and/or radiation therapy with/without neoadjuvant therapy (NAT) or adjuvant therapy under multi-modality guidance; and the other is the palliative therapy or multidisciplinary decision-making with low possibility of curability, based on the characteristics and patterns of diseases at the initial diagnosis. [4][5][6][7][8][9] Except of some specific systemic diseases, patients with an in situ or organ-limited diseases have a better chance to be cured accompanied with a long-term survival after the initial primary curative treatment. 2 However, few patients with proposed curable diseases may recur later even though the initial primary active and curative treatment is given, and subsequently die of diseases, suggesting that an accurate and precise evaluation and appropriate and personalized therapeutic plan to those patients with supposedly curable diseases by far-advanced development of new technology or therapeutic strategy is critically important. 10,11 All efforts make the diseases with a maximal chance for curability. The article published in the January issue of the Journal of the Chinese Medical Association entitled "The clinicopathological and genetic differences among gastric cancer patients with no recurrence, early recurrence, and late recurrence after curative surgery" attempted to explore this topic, since the authors' enrolled subjects belonged to complete resection of tumors and all of them received the curable surgery claimed by authors. 12 The authors enrolled 473 patients with gastric cancer (GC) undergoing curative surgery to investigated the impact of genetic alterations and clinicopathological features on disease-free survival (DFS) and overall survival (OS) in these GC patients. 12 DFS was classified as no recurrence, early recurrence (defined by < 2 years) and late recurrence (defined by ≥ 2 years). 12 The authors found that PIK3CA amplifications in diffuse-type GC were associated with early recurrence and ARID1A mutations were frequently found in patients with single-site recurrence, suggesting that targeted therapy and immunotherapy might be helpful for these patients. 12 The current article is interesting and worthy of further discussion.

show abstract

Is it possible that advanced-stage gastric cancer patients can be cured by surgery alone?

Cited by 6 publications

References 11 publications

The statistical significance may be mis-interpretated

The statistical significance may be mis-interpretated

Reply to “Is it possible that advanced-stage gastric cancer patients can be cured by surgery alone?”

Molecular pathology-integrated clinicopathological prognostic factors

Contact Info

Product

Resources

About